` CVAC (CureVac NV) vs S&P 500 Comparison - Alpha Spread

CVAC
vs
S&P 500

Over the past 12 months, CVAC has underperformed S&P 500, delivering a return of 9% compared to the S&P 500's 12% growth.

Stocks Performance
CVAC vs S&P 500

Loading

Performance Gap
CVAC vs S&P 500

Loading
CVAC
S&P 500
Difference

Performance By Year
CVAC vs S&P 500

Loading
CVAC
S&P 500
Add Stock

Competitors Performance
CureVac NV vs Peers

S&P 500
CVAC
ABBV
AMGN
GILD
VRTX
Add Stock

CureVac NV
Glance View

Market Cap
834.5m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.11 USD
Undervaluation 9%
Intrinsic Value
Price
Back to Top